Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 12/2007

01-12-2007 | Original Paper

The Effect of Acetaldehyde on Human Plasma Factor XIII Function

Authors: Elizabeth A. Suchocki, Arthur S. Brecher

Published in: Digestive Diseases and Sciences | Issue 12/2007

Login to get access

Abstract

The effect of acetaldehyde on the transglutaminase activity in pooled normal human plasma has been investigated. In this study, 0.05, 0.2, and 0.7 ml of pooled human plasma were preincubated for 30 min. at room temperature with buffer or acetaldehyde at final concentrations of 40.6, 22.4, and 11.2 mM before being utilized for Factor XIIIa assay with fibrinogen and thrombin which had been preheated at 40°C to destroy endogenous Factor XIII/XIIIa activity. At all concentrations of acetaldehyde and all concentrations of plasma-containing Factor XIII which were employed, prolongation of both clotting time and stabilization time was observed. The 11.2 mM acetaldehyde is within the range of daily acetaldehyde production to be predicted in severe alcoholics as a consequence of imbibing alcohol. The stabilization times measured for Factor XIIIa activity appear to be the most sensitive to acetaldehyde compared to acetaldehyde effects on thrombin, Factor Xa, and fibrinogen studied earlier in this laboratory, as well as Factors II, VII, and X.
Literature
1.
Podolsky DK, Isselbacher KJ (1994) Alcohol-related liver disease and cirrhosis. In: Harrison’s principles of internal medicine, 13th ed. Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL (eds). McGraw-Hill, New York, pp 1483–1495
2.
Crabb DW, Lumeng L (1989) Alcoholic liver diseases. In: Textbook of internal medicine. Kelly WN (ed). Lippincott, Philadelphia, pp 592–602
3.
Skrzydlewska E, Worowski K (1984–1985) Influence of ethanol and acetaldehyde on blood coagulation. Rocs Akad Med Bialymst 29–30:153–162
4.
Brecher AS (2005) The effect of acetaldehyde on plasma. In: Comprehensive handbook of alcohol related pathology. Preedy VR, Watson R (eds). Academic Press, Elsevier Science, London, pp 1223–1244
5.
Lenehan JG, Smith K (1985) Hemostasis, 17th ed. General Diagnostics, Morris Plains, NJ, p 45
6.
Lelbach WK (1976) Epidemology of alcoholic liver disease. In: Progress in liver diseases. Popper H, Schaffner F (eds). Grune & Stratton, New York, pp 494–515
7.
Brecher AS, Hellman K, Basista MH (1997) A perspective on acetaldehyde concentrations and toxicity in man and animals. Alcohol 14:493–496PubMedCrossRef
8.
Brecher AS, Adamu MT (2002) Short- and long-term effects of acetaldehyde on plasma. Alcohol 26:49–53PubMedCrossRef
9.
Brecher AS, Koterba AP, Basista MH (1996) Coagulation protein function. III. Effect of acetaldehyde upon the activation of prothrombin. Alcohol 13:423–429PubMedCrossRef
10.
Brecher AS, Koterba AP, Basista MH (1996) Coagulation protein function. IV. Effect of acetaldehyde upon factor X and factor Xa, the proteins at the gateway to the common coagulation pathway. Alcohol 13:539–545PubMedCrossRef
11.
Sabol DA, Basista MH, Brecher AS, Haider K, Kleshinski J (1999) Coagulation protein function VII: diametric effects of acetaldehyde on factor VII and factor IX function. Dig Dis Sci 44:2564–2567PubMedCrossRef
12.
Basista MH, Joseph A, Smolen, S, Koterba A, Brecher AS (1994) Acetaldehyde alters coagulation protein function. Dig Dis Sci 39:2421–2425PubMedCrossRef
13.
Hatake K, Taniguchi T, Ouchi H, Sakaki N, Hishida S, Ijiri I (1990) Possible involvement of kinins in cardiovascular changes after alcohol intake. Pharmacol Biochem Behav 35:437–442PubMedCrossRef
14.
Salaspuro M (1991) Epidemiological aspects of alcohol and alcoholic liver disease, ethanol metabolism and pathogenesis of alcoholic liver injury. In: Oxford textbook of clinical hepatology. McIntyre N, Benhamov JP, Bircher J, Rizzetto M, Rodes J (eds). Oxford Press, Oxford, pp 791–810
15.
Watanabe A, Kobayashi M, Hobara N, Nakatsukasa H, Nagashima H, Fujimoto A (1985) A report of unusually high blood ethanol and acetaldehyde levels in two surviving patients. Alcohol Clin Exp Res 9:14–16PubMed
16.
Bordalo O, Batista A, Geraldes J, Neto F, Mascarenhas F, Leitao N, Noronha M, Silva PE (1974) Clinical correlations in alcoholic patients without manifest cirrhosis. Am J Gastroenterol 61:371–378PubMed
17.
Braun KP, Pavlovich JG, Jones DR, Peterson CM (1997) Stable acetaldehyde adducts: structural characterization of acetaldehyde adducts of human hemoglobin N-terminal B-globin chain peptides. Alcohol Clin Exp Res 21:40–43PubMed
18.
Lin RC, Lumeng L, Shahidi S, Kelly T, Pound DC (1990) Protein-acetaldehyde adducts in serum of alcoholic patients. Alcohol Clin Exp Res 14:438–443PubMedCrossRef
19.
Lin RC, Shahidi S, Kelly TJ, Lumeng C, Lumeng L (1993) Measurement of hemoglobin-acetaldehdye adduct in alcoholic patients. Alcohol Clin Exp Res 17:669–674PubMedCrossRef
20.
Nagata N, Nishizaki Y, Watanabe N, Tsuda M, Matsuzaki S (1998) An enzyme immune assay for serum anti-acetaldehyde adduct antibody using low-density lipoprotein adduct and its significance in alcoholic liver injury. Alcohol Clin Exp Res 22(Suppl 3):150S–155SPubMedCrossRef
21.
Nicholls RM, Fowles LF, Worrall S, de Jersey J, Wilce PA (1994) Distribution and turnover of acetaldehyde-modified proteins in liver and blood of ethanol-fed rats. Alcohol Alcohol 29:149–157PubMed
22.
Niemela O (1999) Aldehyde-protein adducts in the liver as a result of ethanol-induced oxidative stress. Front Biosci 4:D506–D513PubMedCrossRef
23.
Niemela O, Israel Y, Mizoi Y, Fukunaga T, Eriksson CJ (1990) Hemoglobin-acetaldehyde adducts in human volunteers following acute ethanol ingestion. Alcohol Clin Exp Res 14:838–841PubMedCrossRef
24.
Niemela O, Parkkila S, Pasanen M, Iimur Y, Bradford B, Thuman RG (1998) Early alcoholic liver injury: formation of protein adducts with acetaldehyde and lipid peroxidation products, and expression of CYP2E1 and CYP3A. Alcohol Clin Exp Res 22:2118–2124PubMedCrossRef
25.
Sorrell MF, Tuma DJ (1987) The functional implications of acetaldehyde binding to cell constituents. Ann NY Acad Sci 492:50–62PubMedCrossRef
26.
Svegliati-Baroni G, Baraona E, Rosman AS, Lieber CS (1994) Collagen-acetaldehyde adducts in alcoholic and nonalcoholic liver diseases. Hepatology 20:111–118PubMedCrossRef
27.
Wickramasinghe SN, Thomas S, Hasan R (1994) Reaction of 14C-acetaldehyde with whole blood in vitro: further evidence for the formation of unstable complexes with plasma proteins and red cells. Alochol Alcohol 29:51–57
28.
Worall S, deJersey J, Wilce PA, Seppa K, Hurme L, Sillinaukee P (1996) Relationship between alcohol intake and immunoglobulin A immunoreactivity with acetaldehyde-modified bovine serum albumin. Alcohol Clin Exp Res 20:836–840CrossRef
29.
Brecher AS, Hellman K, Dulin C Basista MH (1998) Coagulation protein function V: diminution of antithrombin III function by acetaldehyde. Dig Dis Sci 43:1746–1751PubMedCrossRef
Metadata
Title
The Effect of Acetaldehyde on Human Plasma Factor XIII Function
Authors
Elizabeth A. Suchocki
Arthur S. Brecher
Publication date
01-12-2007
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-007-9754-z

Other articles of this Issue 12/2007

Digestive Diseases and Sciences 12/2007 Go to the issue

Original Paper

Oral Proton Pump Inhibitors Are as Effective as Endoscopic Treatment for Bleeding Peptic Ulcer: A Prospective, Randomized, Controlled Trial

Original Paper

Postinfantile Giant Cell Hepatitis Due to Hepatitis E Virus Along with the Presence of Autoantibodies

Case Report

The Beneficial Effect of N-Acetylcysteine and Ciprofloxacin Therapy on the Outcome of Ischemic Fulminant Hepatic Failure

OriginalPaper

Liposarcoma in a Colonic Polyp: Case Report and Review of the Literature

Case Report

An Unusual Case of Hemochromatosis in an African-American Man: Case Report and Review of the Literature

OriginalPaper

Infliximab Delays but Does Not Avoid the Need for Surgery in Treatment-Resistant Pediatric Crohn’ Disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits